Advertisement

Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification

      Highlights

      • BRCA1 p.Val1833Met is a disease-associated variant, more correlated with ovarian cancer.
      • The founder effect of p.Val1833Met variant is established revealing its Greek origin.
      • The estimated overall likelihood ratio (>1) adds further evidence in favor of causality.

      Abstract

      Purpose

      Multiple lines of evidence have suggested a likely causative role in breast/ovarian cancer (BrCa/OvCa) predisposition for the BRCA1 p.(Val1833Met) variant, predominantly found among Greek patients. Our aim was to study the variant's prevalence and founder effect on the Greek population, while providing additional data for its pathogenicity.

      Methods

      We genotyped 3531 BrCa/OvCa patients using Sanger and next generation sequencing, as well as 1558 healthy, age-matched females with real-time PCR. Carriers underwent haplotype analysis to determine a founder effect. A co-segregation analysis was applied to estimate the likelihood ratio for pathogenicity.

      Results

      In total, 27 BrCa/OvCa patients (0.77%; 27/3531) were found to carry the p.(Val1833Met) variant. No carriers were identified in the control group diagnosis. A common shared haplotype, spanning 2.76 Mb on chromosome 17 was demonstrated among carriers, establishing the founder effect. BRCA1, p.(Val1833Met) is possibly a disease-associated variant, supported by a likelihood ratio of 1.88, while a correlation to ovarian cancer is suspected.

      Conclusions

      Altogether, BRCA1, p.(Val1833Met) variant is a Greek founder and is very likely to predispose for BrCa/OvCa. Therefore, such carriers should be counselled accordingly, with clinical recommendations supporting surveillance and risk-reduction strategies, while providing the option for targeted therapeutic interventions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Konstantopoulou I.
        • Tsitlaidou M.
        • Fostira F.
        • Pertesi M.
        • Stavropoulou A.V.
        • Triantafyllidou O.
        • Tsotra E.
        • Tsiftsoglou A.P.
        • Tsionou C.
        • Droufakou S.
        • Dimitrakakis C.
        • Fountzilas G.
        • Yannoukakos D.
        High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
        Clin Genet. 2014; 85: 36-42https://doi.org/10.1111/cge.12274
        • Anagnostopoulos T.
        • Pertesi M.
        • Konstantopoulou I.
        • Armaou S.
        • Kamakari S.
        • Nasioulas G.
        • Athanasiou A.
        • Dobrovic A.
        • Young M.A.
        • Goldgar D.
        • Fountzilas G.
        • Yannoukakos D.
        G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
        Breast Cancer Res Treat. 2008; 110: 377-385https://doi.org/10.1007/s10549-007-9729-y
        • Goldgar D.E.
        • Easton D.F.
        • Deffenbaugh A.M.
        • Monteiro A.N.
        • Tavtigian S.V.
        • Couch F.J.
        Breast cancer information core steering C. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
        Am J Hum Genet. 2004; 75: 535-544https://doi.org/10.1086/424388
        • Easton D.F.
        • Deffenbaugh A.M.
        • Pruss D.
        • Frye C.
        • Wenstrup R.J.
        • Allen-Brady K.
        • Tavtigian S.V.
        • Monteiro A.N.
        • Iversen E.S.
        • Couch F.J.
        • Goldgar D.E.
        A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
        Am J Hum Genet. 2007; 81: 873-883https://doi.org/10.1086/521032
        • Yu X.
        • Chini C.C.
        • He M.
        • Mer G.
        • Chen J.
        The BRCT domain is a phospho-protein binding domain.
        Science. 2003; 302: 639-642https://doi.org/10.1126/science.1088753
        • Stavropoulou A.V.
        • Fostira F.
        • Pertesi M.
        • Tsitlaidou M.
        • Voutsinas G.E.
        • Triantafyllidou O.
        • Bamias A.
        • Dimopoulos M.A.
        • Timotheadou E.
        • Pectasides D.
        • Christodoulou C.
        • Klouvas G.
        • Papadimitriou C.
        • Makatsoris T.
        • Pentheroudakis G.
        • Aravantinos G.
        • Karydakis V.
        • Yannoukakos D.
        • Fountzilas G.
        • Konstantopoulou I.
        Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.
        PLoS ONE. 2013; 8: e58182https://doi.org/10.1371/journal.pone.0058182
        • Landrum M.J.
        • Lee J.M.
        • Benson M.
        • Brown G.R.
        • Chao C.
        • Chitipiralla S.
        • Gu B.
        • Hart J.
        • Hoffman D.
        • Jang W.
        • Karapetyan K.
        • Katz K.
        • Liu C.
        • Maddipatla Z.
        • Malheiro A.
        • McDaniel K.
        • Ovetsky M.
        • Riley G.
        • Zhou G.
        • Holmes J.B.
        • Kattman B.L.
        • Maglott D.R.
        ClinVar: improving access to variant interpretations and supporting evidence.
        Nucleic Acids Res. 2018; 46: D1062-D1067https://doi.org/10.1093/nar/gkx1153
        • Cline M.S.
        • Liao R.G.
        • Parsons M.T.
        • Paten B.
        • Alquaddoomi F.
        • Antoniou A.
        • Baxter S.
        • Brody L.
        • Cook-Deegan R.
        • Coffin A.
        • Couch F.J.
        • Craft B.
        • Currie R.
        • Dlott C.C.
        • Dolman L.
        • den Dunnen J.T.
        • Dyke S.O.M.
        • Domchek S.M.
        • Easton D.
        • Fischmann Z.
        • Foulkes W.D.
        • Garber J.
        • Goldgar D.
        • Goldman M.J.
        • Goodhand P.
        • Harrison S.
        • Haussler D.
        • Kato K.
        • Knoppers B.
        • Markello C.
        • Nussbaum R.
        • Offit K.
        • Plon S.E.
        • Rashbass J.
        • Rehm H.L.
        • Robson M.
        • Rubinstein W.S.
        • Stoppa-Lyonnet D.
        • Tavtigian S.
        • Thorogood A.
        • Zhang C.
        • Zimmermann M.
        • Authors B.C.
        • Burn J.
        • Chanock S.
        • Ratsch G.
        • Spurdle A.B.
        BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
        PLoS Genet. 2018; 14: e1007752https://doi.org/10.1371/journal.pgen.1007752
        • Zhang X.
        • Morera S.
        • Bates P.A.
        • Whitehead P.C.
        • Coffer A.I.
        • Hainbucher K.
        • Nash R.A.
        • Sternberg M.J.
        • Lindahl T.
        • Freemont P.S.
        Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.
        EMBO J. 1998; 17: 6404-6411https://doi.org/10.1093/emboj/17.21.6404
        • Ekblad C.M.
        • Wilkinson H.R.
        • Schymkowitz J.W.
        • Rousseau F.
        • Freund S.M.
        • Itzhaki L.S.
        Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
        J Mol Biol. 2002; 320: 431-442
        • Nikolopoulos G.
        • Pyrpassopoulos S.
        • Thanassoulas A.
        • Klimentzou P.
        • Zikos C.
        • Vlassi M.
        • Vorgias C.E.
        • Yannoukakos D.
        • Nounesis G.
        Thermal unfolding of human BRCA1 BRCT-domain variants.
        Biochim Biophys Acta. 2007; 1774: 772-780https://doi.org/10.1016/j.bbapap.2007.03.018
        • Carvalho M.
        • Pino M.A.
        • Karchin R.
        • Beddor J.
        • Godinho-Netto M.
        • Mesquita R.D.
        • Rodarte R.S.
        • Vaz D.C.
        • Monteiro V.A.
        • Manoukian S.
        • Colombo M.
        • Ripamonti C.B.
        • Rosenquist R.
        • Suthers G.
        • Borg A.
        • Radice P.
        • Grist S.A.
        • Monteiro A.N.
        • Billack B.
        Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
        Mutat Res. 2009; 660: 1-11https://doi.org/10.1016/j.mrfmmm.2008.09.017
        • Lee M.S.
        • Green R.
        • Marsillac S.M.
        • Coquelle N.
        • Williams R.S.
        • Yeung T.
        • Foo D.
        • Hau D.D.
        • Hui B.
        • Monteiro A.N.
        • Glover J.N.
        Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
        Cancer Res. 2010; 70: 4880-4890https://doi.org/10.1158/0008-5472.CAN-09-4563
        • Hayes F.
        • Cayanan C.
        • Barilla D.
        • Monteiro A.N.
        Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
        Cancer Res. 2000; 60: 2411-2418
        • Rowling P.J.
        • Cook R.
        • Itzhaki L.S.
        Toward classification of BRCA1 missense variants using a biophysical approach.
        J Biol Chem. 2010; 285: 20080-20087https://doi.org/10.1074/jbc.M109.088922
        • Coyne R.S.
        • McDonald H.B.
        • Edgemon K.
        • Brody L.C.
        Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.
        Cancer Biol Ther. 2004; 3: 453-457
        • Woods N.T.
        • Baskin R.
        • Golubeva V.
        • Jhuraney A.
        • De-Gregoriis G.
        • Vaclova T.
        • Goldgar D.E.
        • Couch F.J.
        • Carvalho M.A.
        • Iversen E.S.
        • Monteiro A.N.A.
        Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance.
        NPJ Genom Med. 2016; 1: 16001https://doi.org/10.1038/npjgenmed.2016.1
        • Petitalot A.
        • Dardillac E.
        • Jacquet E.
        • Nhiri N.
        • Guirouilh-Barbat J.
        • Julien P.
        • Bouazzaoui I.
        • Bonte D.
        • Feunteun J.
        • Schnell J.A.
        • Lafitte P.
        • Aude J.C.
        • Nogues C.
        • Rouleau E.
        • Lidereau R.
        • Lopez B.S.
        • Zinn-Justin S.
        • Caputo S.M.
        Combining homologous recombination and phosphopeptide-binding data to predict the impact of BRCA1 BRCT variants on cancer risk.
        Mol Cancer Res. 2019; 17: 54-69https://doi.org/10.1158/1541-7786.MCR-17-0357
        • Daly M.B.
        • Pilarski R.
        • Axilbund J.E.
        • Berry M.
        • Buys S.S.
        • Crawford B.
        • Farmer M.
        • Friedman S.
        • Garber J.E.
        • Khan S.
        • Klein C.
        • Kohlmann W.
        • Kurian A.
        • Litton J.K.
        • Madlensky L.
        • Marcom P.K.
        • Merajver S.D.
        • Offit K.
        • Pal T.
        • Rana H.
        • Reiser G.
        • Robson M.E.
        • Shannon K.M.
        • Swisher E.
        • Voian N.C.
        • Weitzel J.N.
        • Whelan A.
        • Wick M.J.
        • Wiesner G.L.
        • Dwyer M.
        • Kumar R.
        • Darlow S.
        Genetic/Familial high-risk Assessment: breast and Ovarian, version 2.2015.
        J Natl Compr Canc Netw. 2016; 14: 153-162
        • Miller S.A.
        • Dykes D.D.
        • Polesky H.F.
        A simple salting out procedure for extracting DNA from human nucleated cells.
        Nucl Acids Res. 1988; 16: 1215
        • Konstanta I.
        • Fostira F.
        • Apostolou P.
        • Stratikos E.
        • Kalfakakou D.
        • Pampanos A.
        • Kollia P.
        • Papadimitriou C.
        • Konstantopoulou I.
        • Yannoukakos D.
        Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
        J Hum Genet. 2018; 63: 1149-1158https://doi.org/10.1038/s10038-018-0498-8
        • Slatkin M.
        • Rannala B.
        Estimating allele age.
        Ann Rev Genomics Hum Genet. 2000; 1: 225-249https://doi.org/10.1146/annurev.genom.1.1.225
        • Mohammadi L.
        • Vreeswijk M.P.
        • Oldenburg R.
        • van den Ouweland A.
        • Oosterwijk J.C.
        • van der Hout A.H.
        • Hoogerbrugge N.
        • Ligtenberg M.
        • Ausems M.G.
        • van der Luijt R.B.
        • Dommering C.J.
        • Gille J.J.
        • Verhoef S.
        • Hogervorst F.B.
        • van Os T.A.
        • Gomez Garcia E.
        • Blok M.J.
        • Wijnen J.T.
        • Helmer Q.
        • Devilee P.
        • van Asperen C.J.
        • van Houwelingen H.C.
        A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.
        BMC Cancer. 2009; 9: 211https://doi.org/10.1186/1471-2407-9-211
        • Pertesi M.
        • Konstantopoulou I.
        • Yannoukakos D.
        Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
        Clin Genet. 2011; 80: 375-382https://doi.org/10.1111/j.1399-0004.2010.01532.x
        • Apostolou P.
        • Pertesi M.
        • Aleporou-Marinou V.
        • Dimitrakakis C.
        • Papadimitriou C.
        • Razis E.
        • Christodoulou C.
        • Fountzilas G.
        • Yannoukakos D.
        • Konstantopoulou I.
        • Fostira F.
        Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.
        Clin Genet. 2016; https://doi.org/10.1111/cge.12824
        • Fernandes V.C.
        • Golubeva V.A.
        • Di Pietro G.
        • Shields C.
        • Amankwah K.
        • Nepomuceno T.C.
        • de Gregoriis G.
        • Abreu R.B.V.
        • Harro C.
        • Gomes T.T.
        • Silva R.F.
        • Suarez-Kurtz G.
        • Couch F.
        • Iversen E.S.
        • Monteiro A.N.A.
        • Carvalho M.A.
        Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: implications for clinical annotation.
        J Biol Chem. 2019; https://doi.org/10.1074/jbc.RA118.005274
        • Golubeva V.N.
        • Monteiro T.
        A. Germline missense variants in BRCA1: new trends and challenges for clinical annotation.
        Preprints. 2019; https://doi.org/10.20944/preprints201902.0090.v1
        • Moghadasi S.
        • Eccles D.M.
        • Devilee P.
        • Vreeswijk M.P.
        • van Asperen C.J.
        Classification and clinical management of variants of uncertain significance in high penetrance cancer predisposition genes.
        Hum Mutat. 2016; 37: 331-336https://doi.org/10.1002/humu.22956
        • Spurdle A.B.
        • Healey S.
        • Devereau A.
        • Hogervorst F.B.
        • Monteiro A.N.
        • Nathanson K.L.
        • Radice P.
        • Stoppa-Lyonnet D.
        • Tavtigian S.
        • Wappenschmidt B.
        • Couch F.J.
        • Goldgar D.E.
        Enigma. ENIGMA–evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
        Hum Mutat. 2012; 33: 2-7https://doi.org/10.1002/humu.21628
        • Moghadasi S.
        • Meeks H.D.
        • Vreeswijk M.P.
        • Janssen L.A.
        • Borg A.
        • Ehrencrona H.
        • Paulsson-Karlsson Y.
        • Wappenschmidt B.
        • Engel C.
        • Gehrig A.
        • Arnold N.
        • Hansen T.V.O.
        • Thomassen M.
        • Jensen U.B.
        • Kruse T.A.
        • Ejlertsen B.
        • Gerdes A.M.
        • Pedersen I.S.
        • Caputo S.M.
        • Couch F.
        • Hallberg E.J.
        • van den Ouweland A.M.
        • Collee M.J.
        • Teugels E.
        • Adank M.A.
        • van der Luijt R.B.
        • Mensenkamp A.R.
        • Oosterwijk J.C.
        • Blok M.J.
        • Janin N.
        • Claes K.B.
        • Tucker K.
        • Viassolo V.
        • Toland A.E.
        • Eccles D.E.
        • Devilee P.
        • Van Asperen C.J.
        • Spurdle A.B.
        • Goldgar D.E.
        • Garcia E.G.
        The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
        J Med Genet. 2018; 55: 15-20https://doi.org/10.1136/jmedgenet-2017-104560
        • Tudini E.
        • Moghadasi S.
        • Parsons M.T.
        • van der Kolk L.
        • van den Ouweland A.M.W.
        • Niederacher D.
        • Feliubadalo L.
        • Wappenschmidt B.
        • Spurdle A.B.
        • Lazaro C.
        Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
        Breast Cancer Res Treat. 2018; 172: 497-503https://doi.org/10.1007/s10549-018-4903-y
        • Daly M.B.
        • Pilarski R.
        • Berry M.
        • Buys S.S.
        • Farmer M.
        • Friedman S.
        • Garber J.E.
        • Kauff N.D.
        • Khan S.
        • Klein C.
        • Kohlmann W.
        • Kurian A.
        • Litton J.K.
        • Madlensky L.
        • Merajver S.D.
        • Offit K.
        • Pal T.
        • Reiser G.
        • Shannon K.M.
        • Swisher E.
        • Vinayak S.
        • Voian N.C.
        • Weitzel J.N.
        • Wick M.J.
        • Wiesner G.L.
        • Dwyer M.
        • Darlow S.
        NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
        J Natl Compr Canc Netw. 2017; 15: 9-20